Literature DB >> 25757039

Does Systolic Blood Pressure Response to Lifestyle Intervention Indicate Metabolic Risk and Health-Related Quality-of-Life Improvement Over 1 Year?

Melanie I Stuckey1, Dawn P Gill, Robert J Petrella.   

Abstract

The purpose of this study was to determine whether responders (minimum 4-mm Hg reduction of systolic blood pressure [BP]) at 24 weeks) to a 52-week lifestyle intervention had greater changes in metabolic risk factors and health-related quality of life than nonresponders. Participants (N=126; age, 57.4 [9.1] years) had waist circumference (WC), resting BP, glycated hemoglobin, lipids, and fitness assessed at baseline and at 12, 24, and 52 months. The 36-item short-form survey was administered to assess HRQOL. At baseline, responders had higher mental health scores (P=.04) and systolic and diastolic BPs (P<.001) than nonresponders. Across 52 weeks, responders also had greater improvements in diastolic BP (P<.001), WC (P=.01), and maximal oxygen uptake (P=.04) compared with nonresponders. Participants with clinically important changes in systolic BP at 24 weeks had greater metabolic improvements across 52 weeks, compared with those without clinically important systolic BP changes. ©2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25757039      PMCID: PMC8031788          DOI: 10.1111/jch.12531

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  24 in total

1.  Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors.

Authors:  Véronique A Cornelissen; Robert H Fagard
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Body mass index, exercise capacity, and mortality risk in male veterans with hypertension.

Authors:  Charles Faselis; Michael Doumas; Demosthenes Panagiotakos; Raya Kheirbek; Lauren Korshak; Athanasios Manolis; Andreas Pittaras; Costas Tsioufis; Vasilios Papademetriou; Ross Fletcher; Peter Kokkinos
Journal:  Am J Hypertens       Date:  2012-01-12       Impact factor: 2.689

Review 4.  Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis.

Authors:  Caroline K Kramer; Bernard Zinman; Ravi Retnakaran
Journal:  Ann Intern Med       Date:  2013-12-03       Impact factor: 25.391

5.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

6.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 7.  Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis.

Authors:  Marc Nocon; Theresa Hiemann; Falk Müller-Riemenschneider; Frank Thalau; Stephanie Roll; Stefan N Willich
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2008-06

8.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

Review 9.  The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.

Authors:  Raj S Padwal; Brenda R Hemmelgarn; Nadia A Khan; Steven Grover; Donald W McKay; Thomas Wilson; Brian Penner; Ellen Burgess; Finlay A McAlister; Peter Bolli; Machael D Hill; Jeff Mahon; Martin G Myers; Carl Abbott; Ernesto L Schiffrin; George Honos; Karen Mann; Guy Tremblay; Alain Milot; Lyne Cloutier; Arun Chockalingam; Simon W Rabkin; Martin Dawes; Rhian M Touyz; Chaim Bell; Kevin D Burns; Marcel Ruzicka; Norman R C Campbell; Michel Vallée; Ramesh Prasad; Marcel Lebel; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

10.  Mobile health, exercise and metabolic risk: a randomized controlled trial.

Authors:  Robert J Petrella; Melanie I Stuckey; Sheree Shapiro; Dawn P Gill
Journal:  BMC Public Health       Date:  2014-10-18       Impact factor: 3.295

View more
  3 in total

1.  Does Systolic Blood Pressure Response to Lifestyle Intervention Indicate Metabolic Risk and Health-Related Quality-of-Life Improvement Over 1 Year?

Authors:  Melanie I Stuckey; Dawn P Gill; Robert J Petrella
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

Review 2.  Metabolic syndrome and quality of life: a systematic review.

Authors:  Patrícia Pozas Saboya; Luiz Carlos Bodanese; Paulo Roberto Zimmermann; Andréia da Silva Gustavo; Caroline Melo Assumpção; Fernanda Londero
Journal:  Rev Lat Am Enfermagem       Date:  2016-11-28

3.  Nutrition and Lifestyle Behavior Peer Support Program for Adults with Metabolic Syndrome: Outcomes and Lessons Learned from a Feasibility Trial.

Authors:  Muhammad Daniel Azlan Mahadzir; Kia Fatt Quek; Amutha Ramadas
Journal:  Nutrients       Date:  2020-04-15       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.